Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Summary

This is a phase 1, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer.

Timeline

Start

2022-01-17

Primary completion

2025-06-18

Completion

2025-06-18

Outcome

Outcome not reported

Stopped: “The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2).”

Drugs

Indications